Gregory Chow Acquires 19,750 Shares of Sutro Biopharma (NASDAQ:STRO) Stock

Key Points

• Gregory Chow, CFO of Sutro Biopharma, acquired 19,750 shares at $0.81 each, totaling approximately $15,997.50, marking a significant increase in his holdings.
• Sutro Biopharma's stock performance shows a 1-year low of $0.52 and a high of $4.60, with a current market capitalization of $68.41 million.
• Recent analysis reports show a consensus rating of "Hold" for Sutro Biopharma, with a target price of $4.47, along with a mix of ratings from analysts, including two "Buy" and two "Sell".

Sutro Biopharma, Inc. (NASDAQ:STRO - Get Free Report) CFO Gregory Chow acquired 19,750 shares of the company's stock in a transaction that occurred on Wednesday, October 15th. The shares were bought at an average cost of $0.81 per share, for a total transaction of $15,997.50. Following the acquisition, the chief financial officer directly owned 19,750 shares in the company, valued at $15,997.50. This represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Sutro Biopharma Price Performance

Shares of NASDAQ:STRO traded up $0.03 on Thursday, hitting $0.81. The company's stock had a trading volume of 722,769 shares, compared to its average volume of 1,116,574. The company has a 50-day simple moving average of $0.88 and a 200 day simple moving average of $0.83. Sutro Biopharma, Inc. has a 1 year low of $0.52 and a 1 year high of $4.60. The company has a market capitalization of $68.41 million, a PE ratio of -0.32 and a beta of 1.61.

Sutro Biopharma (NASDAQ:STRO - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.39) by $0.25. Sutro Biopharma had a negative return on equity of 852.70% and a negative net margin of 201.32%.The firm had revenue of $63.74 million for the quarter, compared to analysts' expectations of $14.55 million. On average, equities research analysts expect that Sutro Biopharma, Inc. will post -2.92 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Sutro Biopharma

Large investors have recently made changes to their positions in the business. RA Capital Management L.P. bought a new stake in shares of Sutro Biopharma during the first quarter valued at approximately $2,885,000. Acadian Asset Management LLC boosted its position in shares of Sutro Biopharma by 78.9% during the first quarter. Acadian Asset Management LLC now owns 3,134,586 shares of the company's stock valued at $2,037,000 after purchasing an additional 1,382,661 shares in the last quarter. Velan Capital Investment Management LP boosted its position in shares of Sutro Biopharma by 197.1% during the second quarter. Velan Capital Investment Management LP now owns 3,060,000 shares of the company's stock valued at $2,185,000 after purchasing an additional 2,030,000 shares in the last quarter. Vestal Point Capital LP boosted its position in shares of Sutro Biopharma by 1.2% during the first quarter. Vestal Point Capital LP now owns 2,600,000 shares of the company's stock valued at $1,692,000 after purchasing an additional 30,000 shares in the last quarter. Finally, AQR Capital Management LLC boosted its position in shares of Sutro Biopharma by 1,052.8% during the first quarter. AQR Capital Management LLC now owns 1,320,917 shares of the company's stock valued at $859,000 after purchasing an additional 1,206,330 shares in the last quarter. 96.99% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

STRO has been the topic of a number of research reports. Weiss Ratings reissued a "sell (e+)" rating on shares of Sutro Biopharma in a report on Wednesday, October 8th. Wells Fargo & Company decreased their price objective on Sutro Biopharma from $4.00 to $3.00 and set an "equal weight" rating on the stock in a report on Tuesday, August 12th. Finally, Wall Street Zen raised Sutro Biopharma from a "sell" rating to a "hold" rating in a research note on Saturday, September 13th. Two analysts have rated the stock with a Buy rating, four have given a Hold rating and two have issued a Sell rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Hold" and a consensus target price of $4.47.

Sutro Biopharma Company Profile

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.